ATL-001 is under clinical development by Achilles Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATL-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATL-001 overview
ATL-001 is under development for the treatment of advanced non-small cell lung cancer and metastatic or recurrent melanoma, head and neck squamous cell carcinoma. The therapeutic candidate comprises of clonal neoantigen T cells (cNeT) isolated from patients own tumor infiltrating lymphocytes (TILs). It is administered through intravenous route.
It was also under development for the treatment of renal cell carcinoma.
Achilles Therapeutics overview
Achilles Therapeutics is a biopharmaceutical company focused on developing personalized T-cell therapies targeting neoantigens present on the surface of cancer cells. It’s lead indications for advanced non-small cell lung cancer and recurrent metastatic melanoma. Achilles uses its proprietary PELEUS bioinformatics platform to identify clonal neoantigens specific to that patient and enable the development of personalized cell therapies targeting cancer cells, without harming healthy tissues. It also operates in Stevenage, Hertfordshire, the UK. Achilles Therapeutics is headquartered in London, Greater London, UK.
For a complete picture of ATL-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
